269 related articles for article (PubMed ID: 19120523)
1. Bladder cancer biomarkers and their role in surveillance and screening.
Van Tilborg AA; Bangma CH; Zwarthoff EC
Int J Urol; 2009 Jan; 16(1):23-30. PubMed ID: 19120523
[TBL] [Abstract][Full Text] [Related]
2. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
3. [Bladder cancer biomarkers].
Dobrowolska-Glazar B; Glazar W; Dobrowolski Z; Lipczyński W
Przegl Lek; 2010; 67(7):479-83. PubMed ID: 21387760
[TBL] [Abstract][Full Text] [Related]
4. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
[TBL] [Abstract][Full Text] [Related]
5. Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative?
de Bekker-Grob EW; van der Aa MN; Zwarthoff EC; Eijkemans MJ; van Rhijn BW; van der Kwast TH; Steyerberg EW
BJU Int; 2009 Jul; 104(1):41-7. PubMed ID: 19500328
[TBL] [Abstract][Full Text] [Related]
6. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings.
Bergman J; Reznichek RC; Rajfer J
BJU Int; 2008 Jan; 101(1):26-9. PubMed ID: 17850364
[TBL] [Abstract][Full Text] [Related]
7. Detection of tumours of the urinary tract in voided urine.
Zwarthoff EC
Scand J Urol Nephrol Suppl; 2008 Sep; (218):147-53. PubMed ID: 18815929
[TBL] [Abstract][Full Text] [Related]
8. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]).
van der Aa MN; Zwarthoff EC; Steyerberg EW; Boogaard MW; Nijsen Y; van der Keur KA; van Exsel AJ; Kirkels WJ; Bangma C; van der Kwast TH
Eur Urol; 2009 Mar; 55(3):659-67. PubMed ID: 18501499
[TBL] [Abstract][Full Text] [Related]
9. The role of nuclear matrix protein 22 combined with bladder tumor antigen stat test in surveillance of recurring bladder cancer.
Xu K; Tam PC; Hou S; Wang X; Bai W
Chin Med J (Engl); 2002 Nov; 115(11):1736-8. PubMed ID: 12609098
[TBL] [Abstract][Full Text] [Related]
10. uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma.
Lodde M; Mian C; Comploj E; Palermo S; Longhi E; Marberger M; Pycha A
Urology; 2006 May; 67(5):950-4. PubMed ID: 16698355
[TBL] [Abstract][Full Text] [Related]
11. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity.
Kamat AM; Karam JA; Grossman HB; Kader AK; Munsell M; Dinney CP
BJU Int; 2011 Oct; 108(7):1119-23. PubMed ID: 21426474
[TBL] [Abstract][Full Text] [Related]
12. Use of urinary biomarkers for bladder cancer surveillance: patient perspectives.
Yossepowitch O; Herr HW; Donat SM
J Urol; 2007 Apr; 177(4):1277-82; discussion 1282. PubMed ID: 17382711
[TBL] [Abstract][Full Text] [Related]
13. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.
Hutterer GC; Karakiewicz PI; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Serretta V; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Perrotte P; Lotan Y; Marberger MJ; Shariat SF
BJU Int; 2008 Mar; 101(5):561-5. PubMed ID: 18257856
[TBL] [Abstract][Full Text] [Related]
14. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma.
Babjuk M; Soukup V; Pesl M; Kostírová M; Drncová E; Smolová H; Szakacsová M; Getzenberg R; Pavlík I; Dvorácek J
Urology; 2008 Apr; 71(4):718-22. PubMed ID: 18387400
[TBL] [Abstract][Full Text] [Related]
15. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology.
Daniely M; Rona R; Kaplan T; Olsfanger S; Elboim L; Freiberger A; Lew S; Leibovitch I
Cancer; 2007 Dec; 111(6):517-24. PubMed ID: 17963263
[TBL] [Abstract][Full Text] [Related]
16. The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer.
Varella-Garcia M; Akduman B; Sunpaweravong P; Di Maria MV; Crawford ED
Urol Oncol; 2004; 22(1):16-9. PubMed ID: 14969798
[TBL] [Abstract][Full Text] [Related]
17. Developing biomarkers for improved diagnosis and treatment outcome monitoring of bladder cancer.
Lintula S; Hotakainen K
Expert Opin Biol Ther; 2010 Aug; 10(8):1169-80. PubMed ID: 20446896
[TBL] [Abstract][Full Text] [Related]
18. Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysis.
Nam RK; Redelmeier DA; Spiess PE; Sampson HA; Fradet Y; Jewett MA
J Urol; 2000 Mar; 163(3):752-7. PubMed ID: 10687970
[TBL] [Abstract][Full Text] [Related]
19. Potential of urinary biomarkers in early bladder cancer diagnosis.
Lam T; Nabi G
Expert Rev Anticancer Ther; 2007 Aug; 7(8):1105-15. PubMed ID: 18028019
[TBL] [Abstract][Full Text] [Related]
20. Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer?--experience at Kuwait University.
Kapila K; Kehinde EO; Anim JT; Mojiminiyi OA; Vinsu A; George SS; Al-Maghrebi M; Al-Mulla F
Cytopathology; 2008 Dec; 19(6):369-74. PubMed ID: 18631356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
